We are live on
!
Find out more
FTM
First Turn Management Portfolio holdings
AUM
$895M
1-Year Est. Return
261.28%
This Fund
S&P 500
This Quarter
Est. Return
+41.3%
1 Year Est. Return
+261.28%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$696M
AUM Growth
–
Cap. Flow
+$566M
Cap. Flow
% of AUM
81.26%
Top 10 Holdings %
Top 10 Hldgs %
48.25%
Holding
31
New
31
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$38.9M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$30.2M |
| 3 |
Legend Biotech
LEGN
|
+$30.2M |
| 4 |
Cytokinetics
CYTK
|
+$29.2M |
| 5 |
Krystal Biotech
KRYS
|
+$26.9M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cytokinetics
CYTK
$10.7B
| $67.4M | 9.68% |
+807,444
| New | +$29.2M |
|
|
CBAY
2
DELISTED
Cymabay Therapeutics
CBAY
| $35.4M | 5.08% |
+1,497,331
| New | +$26.7M |
|
|
3
Vertex Pharmaceuticals
VRTX
$122B
| $33.2M | 4.77% |
+81,683
| New | +$30.2M |
|
|
4
argenx
ARGX
$52.9B
| $31.7M | 4.56% |
+83,403
| New | +$38.9M |
|
5
Xenon Pharmaceuticals
XENE
$6.38B
| $31.3M | 4.5% |
+680,389
| New | +$24M |
|
|
6
Krystal Biotech
KRYS
$10B
| $30M | 4.31% |
+242,185
| New | +$26.9M |
|
|
7
Legend Biotech
LEGN
$4.49B
| $28.6M | 4.11% |
+476,079
| New | +$30.2M |
|
|
KRTX
8
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $27.7M | 3.97% |
+87,369
| New | +$17M |
|
9
Transmedics
TMDX
$2.54B
| $25.5M | 3.66% |
+323,185
| New | +$19.5M |
|
10
Insulet
PODD
$11.6B
| $25M | 3.59% |
+115,366
| New | +$19.8M |
|
|
DAWN
11
DELISTED
Day One Biopharmaceuticals
DAWN
| $24.8M | 3.57% |
+1,700,949
| New | +$20.6M |
|
12
Mirum Pharmaceuticals
MIRM
$7.11B
| $24.7M | 3.55% |
+836,302
| New | +$25.3M |
|
|
VRNA
13
DELISTED
Verona Pharma
VRNA
| $24M | 3.44% |
+1,206,291
| New | +$17.8M |
|
14
DexCom
DXCM
$29.2B
| $23.9M | 3.44% |
+192,932
| New | +$19.7M |
|
15
Axsome Therapeutics
AXSM
$11.4B
| $23.5M | 3.38% |
+295,428
| New | +$19.8M |
|
16
Immunocore
IMCR
$1.73B
| $23.4M | 3.37% |
+343,079
| New | +$17.8M |
|
17
Vaxcyte
PCVX
$8.01B
| $22.5M | 3.22% |
+357,528
| New | +$18.6M |
|
18
Immunovant
IMVT
$8.2B
| $21.6M | 3.1% |
+512,893
| New | +$18.9M |
|
19
Biohaven
BHVN
$2.24B
| $20.4M | 2.93% |
+477,314
| New | +$14.8M |
|
20
Sarepta Therapeutics
SRPT
$1.78B
| $19.7M | 2.82% |
+203,882
| New | +$19.6M |
|
21
Ascendis Pharma A/S
ASND
$16.5B
| $19.1M | 2.74% |
+151,587
| New | +$15.1M |
|
|
NUVL
22
DELISTED
Nuvalent
NUVL
| $18.8M | 2.7% |
+255,897
| New | +$15.8M |
|
23
Ionis Pharmaceuticals
IONS
$8.75B
| $18M | 2.59% |
+356,679
| New | +$17.1M |
|
|
ITCI
24
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $15.6M | 2.24% |
+217,425
| New | +$12.5M |
|
25
Roivant Sciences
ROIV
$24.5B
| $15.3M | 2.2% |
+1,363,504
| New | +$13.3M |
|
Similar funds
WIC
IWP
SI
GEM
BFFIM
WP
SFM
JIR
First Turn Management's Q4 2023 Portfolio in Review
Q4 2023 is the first quarter with a 13F filing on record for First Turn Management, which disclosed 31 positions worth $696M. Its ten largest holdings account for 48% of the portfolio.
Its largest position is argenx: 83,403 shares worth $31.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- First Turn Management's largest Q4 2023 buy was argenx: 83,403 shares worth $31.7M.
- First Turn Management's ten largest holdings make up 48% of its $696M portfolio in Q4 2023.
- First Turn Management disclosed 31 positions in Q4 2023, its first 13F filing on record.
Based on First Turn Management's 13F filing for Q4 2023, filed 8 Feb 2024.